MAPT and Cognitive impairment: To determine whether GQ1b improves cognitive impairments in transgenic mouse models of AD, we used 3xTg-AD mice at advanced stages of the disease (18–22 months), that had already developed Aβ, tau pathology and showed decreased BDNF expression in the hippocampus (Supplementary Fig. 2A–E).